Bristol-Myers, Celgene face US antitrust claims over Pomalyst
MLex Summary: A New York welfare fund filed US antitrust claims accusing Bristol-Myers and Celgene of unlawfully extending a monopoly in the market for pomalidomide, a blockbuster drug used in the...To view the full article, register now.
Already a subscriber? Click here to view full article